FDA guidance
ARANESP, DARBEPOETIN ALFA (VIAL - SUBCUTANEOUS), [AMGEN]
FDA guidance · issued Jun 14, 2024
Key facts
| Title | ARANESP, DARBEPOETIN ALFA (VIAL - SUBCUTANEOUS), [AMGEN] |
|---|---|
| Issue date | Jun 14, 2024 |
| Center | Center for Drug Evaluation and Research |
| Regulated product | Drugs |
| Topics | Medication Guide |
| Document on fda.gov | accessdata.fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents